TRAIL gene expression analysis in multiple sclerosis patients

作者: Mohammad Taheri , Shirin Nemati , Abolfazl Movafagh , Mohammad Saberi , Reza Mirfakhraie

DOI: 10.3233/HAB-160291

关键词: ImmunologyExpanded Disability Status ScaleTumor necrosis factor alphaMedicineReal-time polymerase chain reactionAlleleVitamin D and neurologyGene expressionAge of onsetMultiple sclerosis

摘要: BACKGROUND: Multiple sclerosis (MS) as an autoimmune disorder in which the insulating covers of neurons Central Nervous System are destructed. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is immunomodulatory molecule to protect against T cells hyper activation. METHODS: In this Case-control study, we compare TRAIL gene expression peripheral blood between 50 relapse remitting MS patients and healthy controls by TaqMan Real time PCR. All were negative for HLA-DRB1*15 susceptible allele, normal serum vitamin D, responder Interferon beta. health individuals matched patients. Also, tried find correlation clinical characteristics RESULTS:No statistically significant difference was found mRNA ( p> 0.05). There no age onset, disease duration Expanded Disability Status Scale Kurtzke (EDSS). As IFN-b may have stimulatory effects on immunoregulatory function all our treated with interferon beta responder, it lead change expression. We suggest comparing responders non-responders should be investigated.

参考文章(24)
Mohammad Mahdi Eftekharian, Mehrnoush Mousavi, Mona Bahmani Hormoz, Ghodratollah Roshanaei, Mehrdokht Mazdeh, Multiple sclerosis and immunological-related risk factors: results from a case-control study. Human antibodies. ,vol. 23, pp. 31- 36 ,(2015) , 10.3233/HAB-150281
A. Kurne, D. Guc, H. Canpinar, Ö. F. Aydin, G. Sayat, M. Yörübulut, G. Esendagli, R. Karabudak, Analysis of BAFF and TRAIL expression levels in multiple sclerosis patients: evaluation of expression under immunomodulatory therapy. Acta Neurologica Scandinavica. ,vol. 123, pp. 8- 12 ,(2011) , 10.1111/J.1600-0404.2010.01346.X
Jan D. Lünemann, Sonia Waiczies, Stefan Ehrlich, Uwe Wendling, Bibiane Seeger, Thomas Kamradt, Frauke Zipp, Death Ligand TRAIL Induces No Apoptosis but Inhibits Activation of Human (Auto)antigen-Specific T Cells Journal of Immunology. ,vol. 168, pp. 4881- 4888 ,(2002) , 10.4049/JIMMUNOL.168.10.4881
Brendan Hilliard, Andreas Wilmen, Cheryl Seidel, Tzu-Shang T. Liu, Rüdiger Göke, Youhai Chen, Roles of TNF-Related Apoptosis-Inducing Ligand in Experimental Autoimmune Encephalomyelitis The Journal of Immunology. ,vol. 166, pp. 1314- 1319 ,(2001) , 10.4049/JIMMUNOL.166.2.1314
F Gilli, F Marnetto, M Caldano, A Sala, S Malucchi, M Capobianco, A Bertolotto, Biological markers of interferon-beta therapy: comparison among interferon-stimulated genes MxA, TRAIL and XAF-1 Multiple Sclerosis Journal. ,vol. 12, pp. 47- 57 ,(2006) , 10.1191/135248506MS1245OA
Mohamed H. Tawdy, Maged M. Abd el Nasser, Sanaa S. Abd el Shafy, Mona A.F. Nada, Mohamed Nasr I. El Sirafy, Amany Hussien Abol Magd, Role of serum TRAIL level and TRAIL apoptosis gene expression in multiple sclerosis and relation to brain atrophy. Journal of Clinical Neuroscience. ,vol. 21, pp. 1606- 1611 ,(2014) , 10.1016/J.JOCN.2013.11.056
A Compston, The 150th anniversary of the first depiction of the lesions of multiple sclerosis. Journal of Neurology, Neurosurgery, and Psychiatry. ,vol. 51, pp. 1249- 1252 ,(1988) , 10.1136/JNNP.51.10.1249
Mohsen Khademi, Erik Wallström, Magnus Andersson, Fredrik Piehl, Roberto Di Marco, Tomas Olsson, Reduction of Both Pro- And Anti-Inflammatory Cytokines After 6 Months of Interferon beta-1a Treatment of Multiple Sclerosis Journal of Neuroimmunology. ,vol. 103, pp. 202- 210 ,(2000) , 10.1016/S0165-5728(99)00184-8